McKesson Reports Fiscal Q2 2027 Revenue of $110.96 Billion, Raises EPS Guidance
Fiscal Q2 revenue rose 8% year over year to $110.96 billion, while adjusted EPS was $11.68 and exceeded analyst estimates. McKesson raised fiscal 2027 adjusted EPS guidance to $45.60–$46.40. The company also extended its CVS Health drug distribution agreement through June 2032 and plans to acquire about 49% of Option Care Health for $1.4 billion, subject to closing conditions.
McKesson reported fiscal Q2 2027 revenue of $110.96 billion, an 8% increase year-over-year, with adjusted EPS of $11.68, exceeding analyst estimates. Following these results, the company raised its fiscal 2027 adjusted EPS guidance to a range of $45.60—$46.40. Strategically, McKesson extended its drug distribution agreement with CVS Health through June 2032 and announced plans to acquire approximately 49% of Option Care Health for $1.4 billion, subject to closing conditions.
Additionally, the company confirmed the completion of its acquisition of Precision Medicine Group on November 2, 2026, and reiterated its intent to separate its medical-surgical solutions segment into an independent company.